• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Raise your hand if you bought the dip on AbbVie today?









so agree with your assessment that stock is stale..... IMO struggling to stay above $90....
with Humira imminent headwinds, my broker thinks ABBV will probably fall another 20% by EOY

AbbVie has too many idiots now, just look at the posts on this board and others.
It’s embarassing.
Dumb reps Dumb’er managers who hired them both destined to fail.